{
    "nct_id": "NCT03121352",
    "official_title": "Pilot Study of Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer",
    "inclusion_criteria": "* Subjects must have histologically or cytologically confirmed metastatic triple negative breast cancer\n* Subjects must have received no more than 2 prior therapies for this disease\n* ECOG Performance Status 0-1\n* Subjects must have normal organ and marrow function as defined below:\n\n  * Hemoglobin ≥ 10.0 g/dl\n  * Absolute neutrophil count ≥ 1,000/μL\n  * Platelet count ≥ 100,000/μL\n  * Total bilirubin within normal institutional limits\n  * AST (SGOT) ≤ 2.5 X institutional upper limit of normal\n  * ALT (SGPT) ≤ 2.5 X institutional upper limit of normal\n  * Serum creatinine ≤ 1.5 normal institutional limits\n* Life expectancy of 12 weeks or more\n* Subjects must have the ability to understand and the willingness to sign a written informed consent document\n* Subjects must have measurable disease per RECIST v1.1\n* Subjects must be willing to undergo a preliminary biopsy of a metastatic focus for research purposes. A second post-treatment biopsy will be offered but will not be mandated\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment toxicities have not resolved to ≤ Grade 1 according to NCI CTCAE Version 4.0 (except for alopecia and neuropathy)\n* Subjects receiving any other investigational agents\n* Subjects with radiographically stable treated brain metastases are eligible but must not have been on steroid therapy for at least 4 weeks\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to nab-paclitaxel, carboplatin, pembrolizumab, or other agents used in this study\n* Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Pregnant or breastfeeding women are excluded from this study\n* Patients with conditions requiring immunosuppressive medications or chronic infections (including HIV infection, hepatitis B and C)\n* Patients with chronic autoimmune disease\n* Patients with prior therapy with antibodies that modulate T-cell function (e.g., anti-PD-1, anti-PD-L1)\n* Patients with evidence of active, non-infectious pneumonia\n* Patients active infection requiring intravenous systemic therapy\n* Patients with known psychiatric or substance abuse disorders that would interfere with cooperation with requirements of the trial\n* Patients who have received a live vaccine within 30 days prior to the first dose of pembrolizumab\n* Patients with a known additional malignancy that is progressing or requires active treatment (within the last 5 years). Exceptions: basal cell carcinoma of the skin, squamous cell carcinoma of the skin or in situ cervical cancer that has undergone potentially curative therapy\n* Patients who have received monoclonal anti-cancer antibody within 4 weeks of first dose of study drugs\n* Patients who have received chemotherapy, small molecule targeted therapy or radiation within the 2 weeks of first dose of study drugs\n* Patients who have participated in MK-3475 Merck studies\n* Patients with carcinomatous meningitis",
    "miscellaneous_criteria": ""
}